Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Sneez, LLC Selected as a Venture Atlanta 2020 Showcase Company


Image of simple survey that screens for what the CDC recognizes as symptoms of COVID-19

Access to real-time health screening and tracking information is more important now than ever, and Sneez delivers.

Sneez, LLC announced today that it has been chosen out of a record-breaking 400 applicants as one of the top technology companies in the Southeast to present at Venture Atlanta 2020. Now in its 14th year, the annual conference to be held October 21-22, pivoted to a fully virtual format, Venture Atlanta Live Online. One of the nation’s best venture capital conferences continues to showcase innovators from the hottest tech markets in the US and boosts its largest number of selected companies and represented investor funds to date. Even in light of COVID-19, Venture Atlanta continues to fuel capital and growth, serving the needs of the region’s vibrant tech community.

“We are honored to have been selected as a Showcase Company of Venture Atlanta 2020,” said Sneez, LLC CEO, Danielle Lamphier. “Our portfolio of health and wellness technology solutions is rapidly gaining traction, and this opportunity to network with other growth minded innovators and investors couldn’t be more timely. Access to real-time health screening and tracking information is more important now than ever, and Sneez delivers.”

Sneez, LLC, is the creator of the leading mobile application for real-time illness tracking, the Sneez app. The company recently added SneezSafe to its portfolio of wellness technology solutions. This new web-based tool is designed for employers and other organizations, such as colleges and universities, to enable employees to screen for symptoms associated with COVID-19 each day before going to work or class. The customizable tool uses the latest CDC guidelines and decision logic to process user data instantly, directing users to seek further evaluation or connect to care when needed – right from the platform. SneezSafe features a robust employer reporting dashboard and is approved by the Institutional Review Board (IRB) to serve as a data gathering tool for the Community Research Partnership National COVID-19 Study conducted through Wake Forest University School of Medicine.

“Venture Atlanta has become the authority for recognizing technology innovation across the Southeast and beyond, connecting the best and brightest innovators with top-tier, national investors and other leaders in our technology ecosystem that helps drive success and results with over $4.5 billion in funding awarded to date,” said Venture Atlanta CEO Allyson Eman. “This year, we’ve pivoted to a digital format to best serve the needs of our vibrant tech community and are thrilled to be showcasing our largest line up of companies ever. These companies reflect our incredible pool of talented people, inspiring innovation, and continued opportunities for growth within the technology community.”

Venture Atlanta Live Online will offer an unparalleled experience that streams two days of immersive events and interactive networking opportunities. Attendees will be able to connect with others at the conference, set up one-on-one meetings, stroll the virtual show floor, watch pitches in real-time, and use features like live chat, and audience polling. Atlanta-based independent investment management firm, Invesco, is this year’s premier sponsor, with Cherry Bekaert, Nelson Mullins and Truist as additional headline sponsors. Venture Atlanta Live Online will conclude with TechSquare Labs’ Atlanta Startup Battle, in which top five companies will pitch on stage against one another to win a $100,000 investment.

To learn more about the Sneez, LLC, portfolio of products, visit http://www.sneezapp.com and http://www.sneezsafe.com. For additional information about Venture Atlanta, to register for the event or to view the conference schedule, please visit http://www.ventureatlanta.org.

About Venture Atlanta

Venture Atlanta, the Southeast’s technology innovation event, is where the region’s most promising tech companies meet the country’s top-tier investors. This year’s event is going all digital through Venture Atlanta Live Online.

As the Southeast’s largest investor showcase helping launch more than 400 companies and raise over $4.5 billion in funding to date, the event connects the region’s top entrepreneurs with local and national investors and others in the technology ecosystem who can help them raise the capital they need to grow their businesses. The annual non-profit event is a collaboration of the Atlanta CEO Council, Metro Atlanta Chamber and the Technology Association of Georgia (TAG). For more information, visit http://www.ventureatlanta.org. For updates, follow us on Twitter and visit our blog.

About Sneez, LLC

Sneez, LLC, uses technology and health data integration to help local communities stay informed and healthy. The Sneez brand was born when pediatric doctors, William Satterwhite, MD and Steven Hodges, MD, created the Sneez app in 2016 – the first of its kind real-time illness tracking app. The Sneez app uses diagnosis data from local physicians and urgent care locations to inform the public of a variety of sicknesses occurring in their specific geography, including flu, colds, strep throat and other common illnesses. This data is used to create a virtual heat map of illnesses circulating in local communities by zip code. The app also helps consumers and their families connect with local healthcare providers through scheduling in-office and virtual visits with providers, as well as equipping users with helpful information such as the wait times at their local emergency room.

In response to COVID-19, Sneez has launched SneezSafe, a workplace solution for health screening and care. The web-based platform screens employees and other community members for COVID-19 through a simple daily survey and connects them with healthcare providers for evaluation and treatment. For more information, please visit http://www.sneezapp.com and http://www.SneezSafe.com. For updates, follow us on LinkedIn.

# # #

Share article on social media or email:

Goliath Technologies’ CEO Thomas Charlton Recognized as Top Influential Leader in MedTech


Thomas Charlton, CEO of Goliath Technologies Named Leader in for Healthcare IT

Thomas Charlton, CEO of Goliath Technologies Named Leader in MedTech

“Goliath’s success is a direct result of the efforts of our team who are passionate about helping alleviate the pains Health IT experience daily,” says Thomas Charlton, Chairman and CEO of Goliath Technologies.

Improving Clinician Experience with EHR applications has made Goliath the Standard in Health IT

Goliath Technologies, with technology that is purpose-built to improve clinician experience and patient care when using EHR applications, announced today that Insight Success, a leading business magazine for entrepreneurs and technology, named Thomas Charlton, Chairman and CEO, one of the top ten influential leaders in MedTech.

Under Charlton’s leadership, Goliath has become a standard in Health IT, with technical and/or business relationships with all four major Electronic Health Record (EHR) providers (Cerner, Epic, MEDITECH, and Allscripts). Health systems improve clinician experience by leveraging the performance metrics Goliath correlates into a single view from their EHR application, end-user experience, and the Citrix or VMware Horizon delivery infrastructure. IT Pros can then anticipate, troubleshoot, and document end-user experience issues more effectively to improve system performance for the medical staff. The ultimate impact to health systems is improved patient care.

“Healthcare clients require purpose-built technology to solve very specific issues faced by today’s Health IT departments,” shares Charlton. “An enterprise IT department will have twice the budget and people to support the same number of users as the health system does. And, in Health IT, patient care is ultimately in the balance if IT systems don’t perform optimally. At Goliath, we have developed technology that has built-in automation and intelligence to address these challenges and has proven to have the net effect of adding three full-time employees to a health system’s staff.”

With Goliath’s embedded intelligence and automation, health systems can easily discover their entire Citrix or VMware Horizon environment and identify what to monitor, the thresholds to set, and then alert when thresholds are exceeded. The software does this for all potential events, conditions, and failure points regarding end-user performance issues when accessing and using their EHR systems along with other business and clinical applications.

“In Insights Success’ latest edition, The 10 Most Influential Leaders in MedTech, we focus on the vital contribution of exceptional technology leaders in the area of healthcare. Thomas Charlton, Chairman and CEO of Goliath Technologies, is an innovator and leader in MedTech. With Goliath, he has brought disruptive changes to healthcare IT, helping them deliver on their ultimate mission of delivering high-quality patient care. Insights Success recognizes and appreciates his contribution, and is honored to feature him in this issue,” states Pooja M. Bansal, Editor-in-Chief at Insight Success.

“I am honored to be recognized by Insights Success in leading the area of MedTech. Once the right market and product has been established, my focus is on building the right team to bring that technology into market and continue to ensure its value is recognized across all health systems. Goliath’s growth and success is a direct result of the efforts of our team who are passionate about helping alleviate the pains Health IT experience daily,” says Charlton.

About Goliath Technologies

Goliath Technologies offers end-user experience monitoring and troubleshooting software, with embedded intelligence and automation, that enables IT pros to anticipate, troubleshoot, and document performance issues regardless of where workloads, applications, or users are located. By doing so, Goliath helps IT break out of reactive mode, and into proactive mode. Customers include Universal Health Services, Ascension, CommonSpirit, Penn National Insurance, American Airlines, Office Depot, Tech Mahindra, Pacific Life, Xerox, HCL, and others. Learn more about how we empower proactive IT at goliathtechnologies.com.

Share article on social media or email:

Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders – Quantitative Skeletal Muscle MRI in Clinical Trials, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

The recent development of quantitative skeletal MRI biomarkers, describing the extent of muscle atrophy and muscle fat infiltration and replacement, has enabled the detection and measurement of NMD earlier and more precisely compared to clinical endpoints.

Drug development in neuromuscular disorders needs robust biomarker and clinical endpoints to study drug efficacy in early and late stage trials. Ultimately, functional decline and motor disability are the main clinical manifestations of neuromuscular disorders (NMD) and used for approval of novel therapeutics. However, assessment of changes in neurological function is associated with large variability and many NMDs are slowly progressive, thus limiting its feasibility as efficacy endpoint in early clinical development.

One of the most promising efficacy biomarkers in neuromuscular disorders for early clinical development is skeletal muscle MRI. The recent development of quantitative skeletal MRI biomarkers, describing the extent of muscle atrophy and muscle fat infiltration and replacement, has enabled the detection and measurement of NMD earlier and more precisely compared to clinical endpoints. Standardized quantitative skeletal muscle MRI has been used to objectively evaluate NMD across different disease stages and measure longitudinal changes in diseases with complex onset patterns and slow progression such as FSHD (facioscapulomuscular dystrophy) and DMD (Duchenne Muscular Dystrophy).

Join Sarah Sherlock, PhD, Director Clinical and Translational Imaging, Pfizer, Diego Cadavid, MD, Senior Vice President, Clinical Development, Fulcrum Therapeutics and Per Widholm, MD, Lead Scientist, MSK, AMRA Medical Research in a live webinar on Wednesday, October 7, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Muscle Fat Replacement and Functional Decline in Neuromuscular Disorders – Quantitative Skeletal Muscle MRI in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Defining, Designing and Deploying Digital Biomarkers in Clinical Trials, Upcoming Webinar Hosted by Xtalks


Xtalks Logo

Xtalks Life Science Webinars

From concerns surrounding regulatory acceptance to defining digital endpoints and deployment plans and digital data collection, there are many factors to consider before incorporating new tools and processes into a clinical trial.

Many drug development sponsors are interested in understanding how a digital biomarker strategy can improve patient-centricity their trial. However, may feel uncertain about where – and sometimes even why – to start. From concerns surrounding regulatory acceptance to defining digital endpoints and deployment plans and digital data collection, there are many factors to consider before incorporating new tools and processes into a clinical trial.

This educational webinar is ideal for drug development sponsors that want to learn about the role of digital biomarkers in clinical trials and hear from several thought leaders as they discuss the key concerns with digital biomarker technologies, their implementation and regulatory acceptance. With a focus on strategic design and considerations for creating digital endpoints as part of an overarching deployment plan, the presenters will also cover many of the key pillars in the adoption and implementation of digital devices in a today’s “new normal” with decentralized or hybrid clinical trial elements.

Register today to be a part of this timely and highly relevant discussion that will also offer attendees a chance to pose their own questions and get real-time responses from several thought leaders.

Join Jennifer Goldsack, MChem, MA, MBA, Executive Director, Digital Medicine Society (DiMe), Christian Knaus, Senior Director, Client Development, SnapIoT Inc., Cristina Green, Executive Director, Decentralized Clinical Trials, Covance and Jane Myles , Director, Decentralized Trials Implementation, Covance in a live webinar on Wednesday, October 7, 2020 at 10am EDT (3pm BST/UK).

For more information or to register for this event, visit Defining, Designing and Deploying Digital Biomarkers in Clinical Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

ASNC Releases New App to Support Cardiovascular Imaging Professionals


News Image

By putting the most current recommendations for diagnosis and treatment at clinicians’ fingertips, the app will further ASNC’s mission of improving cardiovascular outcomes through image-guided patient management.

A new smart-device application released today by the American Society of Nuclear Cardiology (ASNC) will make it easier for cardiovascular healthcare professionals to learn and implement the latest evidence-based imaging to improve patient care. The “ASNC Clinical and Quality Resources App” contains key guidelines and educational materials in a single electronically searchable portal. It also offers the most up-to-date guidance on cardiac amyloidosis care in eight languages: Chinese, English, French, German, Italian, Japanese, Portuguese and Spanish.

“ASNC’s new clinical and quality resources app is a contemporary tool designed to help busy healthcare professionals,” says ASNC President Sharmila Dorbala, MD, MPH, FASNC, Director of Nuclear Cardiology at Brigham and Women’s Hospital and Associate Professor of Radiology at Harvard Medical School. “By putting the most current recommendations for diagnosis and treatment at clinicians’ fingertips, the app will further ASNC’s mission of improving cardiovascular outcomes through image-guided patient management.”

The resources app includes the latest guidelines, expert consensus documents and information statements across the field of nuclear cardiology and molecular imaging. Topics include SPECT and cardiovascular PET protocols; best practices for cardio-oncology and imaging in women; and the latest guidance for standardized imaging methods, diagnostic criteria and appropriate imaging utiization in the rapidly evolving area of cardiac amyloidosis.

“As the paradigm for cardiac amyloidosis screening, diagnosis and treatment has shifted in recent years, ASNC has launched initiatives to ensure today’s clinicians have the information they need to deliver optimal care,” says Dr. Dorbala. “The ASNC Clinical and Quality Resources App will make it easy and efficient for cliniicians to access the essential guidelines and practice points in their preferred language.”

ASNC partnered with nuclear cardiology/medicine organizations from around the world to ensure that the app will meet the needs of clinicians no matter where they practice. Collaborating organizations include the Chinese Society of Nuclear Medicine, French Society of Nuclear Medicine, German Society of Nuclear Medicine, Italian Association of Nuclear Medicine, Japanese Society of Nuclear Cardiology, Latin American Association of Nuclear Medicine and Biology, Portuguese Society of Nuclear Medicine and Spanish Society of Nuclear Medicine.

Designed for iOS and Android platforms, the ASNC Clinical and Quality Resources App also makes it easy for users to access news and updates from the Society, including the Journal of Nuclear Cardiology, the ImageGuide Registry®, and the latest online educational opportunities.

“We are grateful the many experts around the world who contributed to the ASNC Clinical and Quality Resources App,” says Kathleen B. Flood, ASNC CEO, “and we thank Pfizer and our sponsors for their partnership and commitment to global education for the achievement of best practices in nuclear cardiology.”

The ASNC Clinical and Quality Resources App is available for free download in the Apple App Store and Google Play. Additional information will be available at ASNC2020: The 25th Annual Scientific Session and Exhibition in the ASNC Exhibitor Showcase Booth. Register for ASNC2020 at http://www.asnc.org/register.

About the American Society of Nuclear Cardiology

For over 25 years, the American Society of Nuclear Cardiology and its more than 4,000 members have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development. ASNC provides peer-reviewed original articles through its official publication Journal of Nuclear Cardiology and operates the nation’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. For more information, visit http://www.asnc.org or follow us on Twitter @MyASNC.

Share article on social media or email:

Lauderhill County Line Chiropractic Provides Helpful Tips on Grocery Curbside Pick-up During COVID-19 Pandemic


County Line Chirporactic Lauderhill, FL - Car Accident Victims

“Injury begins at impact. Visit a chiropractor as soon as possible,” Dr. Solivan suggested. “We will access your injuries and determine the next steps to get you on the road to recovery.”

As people focus on social distancing and reducing their contact with others, many have turned to grocery delivery and curbside pick-up. With new designated parking areas, grocery curbside pick-up can cause some confusion, leading to potential car accidents. Lauderhill County Line Chiropractic Medical & Rehab Center has offered some insightful tips to ensure that visits to grocery stores are safe and easy for everyone.

“Our first tip is to park in the designated areas of the parking lot for grocery pickup,” said Dr. Solivan, Lauderhill Chiropractor. “Most grocery stores have designated parking spots that help to keep the flow of traffic moving and ensure that employees know where to go with your delivery.”

Most stores have parking spots right near the front of the store that are specifically designated as “pickup” spots. They are designed to help expedite the loading process, so people aren’t waiting around for their groceries.

“Try to park somewhere that doesn’t impede traffic. Sitting in the fire lane makes you an easy target for people to sideswipe your car,” Dr. Solivan explained. “It can also cause issues in the event of a fire or other emergency situation.”

After picking up your groceries, be sure to pull out slowly, look in all directions, wear your seatbelt, and use caution, as many people are trying to get away from public areas quickly. While it may seem like an overreaction while in a parking lot, it can mean the difference between a few days of soreness and a long-term injury.

If you have been involved in a car accident in a parking lot, you should know that injuries can occur even when you are going 5 MPH or less – or even if you are parked and someone hits your vehicle from behind. How you respond to that injury from the second you get it will determine what your recovery process looks like.

“Injury begins at impact. Visit a chiropractor as soon as possible,” Dr. Solivan suggested. “We will access your injuries and determine the next steps to get you on the road to recovery.”

Remember, accident victims may not even recognize that they have an injury until a few days later, which is why it’s essential to get checked out by a medical professional in the event of any accident. Carrying in heavy bags of groceries and household supplies can worsen these injuries.

If you are injured in a grocery store parking lot, you may require some chiropractic care for a smooth recovery. The County Line Chiropractic Lauderhill office is located at 5425 N University Drive, Fort Lauderdale, FL 33351. The Lauderhill location hours are:

  • Monday, Wednesday, and Friday 9 a.m. – 7 p.m.
  • Tuesday and Thursday 2 p.m. – 7 p.m.
  • Saturday 9 a.m. – 12 p.m.

For more information about car accidents and patient care, visit the County Line Chiropractic website.

More About County Line Chiropractic

At County Line Chiropractic, our mission is to help our patients find pain relief through natural recovery. Our experienced Chiropractors are determined to find the source of your injury and design a customized care plan to heal your body effectively and naturally to reduce long-term or chronic pain.

We have six locations in South Florida: Lauderhill, North Miami Beach, Miami Gardens, Pembroke Pines, Plantation, and East Fort Lauderdale that are ready to help you. We offer chiropractic care to anyone suffering from chronic pain or muscle aches and pains, as well as victims of work or auto injuries. Our chiropractors in the Broward and Miami-Dade counties help develop customized, non-invasive plans for quick and long-term chiropractic care.

For more information, please visit the County Line Chiropractic website (https://www.countylinechiro.com/) or call 800-811-1231.

Share article on social media or email:

Acutis Diagnostics Receives New York State Approval for Comprehensive Urinary Tract Infection Assay


With approval from the New York State Department of Health, Acutis will become the first laboratory that is able to offer such testing in all 50 states.

Acutis Diagnostics, a vertically integrated company serving the medical and pharmaceutical communities by providing rapid and reliable diagnostic insights that impact clinical decisions in infectious disease, announced today that it has received approval from the New York State Department of Health for its Acutis Reveal™ Urinary Tract Infection molecular assay. Based on a custom designed microarray, the Reveal™ UTI can simultaneously test for the presence of 31 bacteria and fungi that are among the most common pathogens associated with such infections. With approval from the New York State Department of Health, Acutis will become the first laboratory that is able to offer such testing in all 50 states.

“This is a tremendous milestone as we expand our infectious disease footprint. The current pandemic has placed a bright spotlight on companies in the infectious disease market, and the ability for our R&D team to be the first in the nation to successfully go through the rigorous process of a New York approval illustrates the high scientific standards that we employ,” says Acutis CEO, Jibreel Sarij.

Impacting more than 150 million individuals each year, urinary tract infections (UTI) are the second most common infection observed globally. In the US, they account for over 10 million office visits, 3 million Emergency Department encounters and half a million hospitalizations, at a total cost of over $6 billion to the healthcare system yearly. Additionally, UTIs are a leading cause of infection-related hospitalization events in the elderly population. Studies have shown that by utilizing assays such as Acutis Reveal™ UTI, material improvements in overall healthcare costs can be achieved.

Acutis scientists previously presented some of the validation findings of the assay, which was developed on the Thermo Fisher Scientific QuantStudio™ platform, at the most recent meeting of the Association for Molecular Pathology. At that presentation, the Company detailed some of the rigorous testing required as part of the New York State approval process, including analyzing each individual assay against actual intact organisms for such specificity, sensitivity linearity and stability. In addition, the Acutis team designed a standardized extraction process for nucleic acids, which it has already employed in its current SARS-CoV-2 assay, thus allowing for improved yield and increased assay throughput.

Managing Director of Acutis Biosciences, David Goldberg explains, “We recognize the scientific progress that Acutis continues to make. This UTI assay will improve patient care as well as provide value for CRO and diagnostic partners. We anticipate further test approvals in both the infectious disease and genomics markets which will help to solidify Acutis’ position as an industry innovator.”

Share article on social media or email:

NeoTract Designates Dr. Kevin Gee as UroLift® Center of Excellence


News Image

“Dr. Kevin Gee has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Kevin Gee, M.D., Madison Medical Affiliates in Mequon, WI, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Gee has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Kevin Gee has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

NES Health to Provide Round-the-Clock Customer Support for Practitioners Around the Globe


NES Health, a world leader in bioenergetics, is expanding the hours available to better assist practitioners and offer help whenever support is needed.

NES Health offers a comprehensive bioenergetics scanning system and software to health and wellness practitioners to help them enhance their business and increase profit.

This system, the Bioenergetix WellNES System, is a combination of ancient wellness traditions and 30 years of scientific research completed by the founders of NES Health. This research has propelled those traditions well into the future.

Currently, over 5,000 practitioners use the system to discover distortions and blockages in the body’s energy fields. By addressing these blockages, practitioners are able to support the health of their clients at the very root.

“Our mission is to help everyone restore their energy for life. Our practitioners are often the first point of contact for those trying to support their health. That’s why we are fully dedicated to lending a hand to the practitioners using our system,” says Chief Marketing Officer, Tom Klausing.

Practitioners using the Bioenergetix WellNES System represent a wide swath of the health community. It is a diverse group ranging from nutritionists to chiropractors to kinesiologists to other professionals looking to help support the health of their clients in natural ways.

Each discipline and its clients has its own unique needs. Those needs often involve simply answering questions related to NES Health products, the best way to help clients, marketing material needs, or myriad other issues.

Kimberly Lackey, Chief Success Officer, elaborates, “While our practitioners typically only work between 9 am and 5 pm, they often need assistance outside of those hours. We now have the capability to help them whenever they need it.”

For more information about the Bioenergetix WellNES System and how to become a NES Health Practitioner, please visit http://www.neshealth.com

Share article on social media or email:

DQE Adds NanoBio Protect Nasal Antiseptic to Its Infection Control Protection Line


Applied with a cotton nasal swab to the skin inside and around the nose, NanoBio Protect kills germs on contact and continues to kill germs for 4+ hours after application.

DQE, partnering with BlueWillow Biologics, is now the healthcare and public safety distributor of the patented NanoBio Protect nasal antiseptic solution. Healthcare and public safety workers are in constant contact with unknown pathogens out in our community. Actions like frequent handwashing, wearing a protective mask, and using hand sanitizers are all important infection control practices that add layers of protection to prevent illness. The nose is a key entry point for most respiratory infections, so using a nasal antiseptic adds another layer of safety. Applied with a cotton nasal swab to the skin inside and around the nose, NanoBio Protect kills germs on contact and continues to kill germs for 4+ hours after application.

Moisturizing and non-irritating NanoBio Protect is safe for everyday use. NanoBio Protect’s active ingredient is benzalkonium chloride (BZK), a topical antiseptic approved by the FDA that has been safely used in over-the-counter antiseptic products for more than 75 years. NanoBio Protect’s patented nanotechnology places the BZK antiseptic on nano-droplets that are small enough to reach germs that hide in layers of skin, but big enough to not be absorbed through the skin into the body. Unlike other nasal sanitizers, NanoBio Protect is alcohol-free, so it does not dry out skin, which leads to irritation and cracking that can allow germs to enter.

Use NanoBio Protect every 4–8 hours, as needed, in combination with other common protective measures, including handwashing, wearing a mask, and social distancing. Wearers include doctors, EMS professionals, firefighters, janitorial staff, nurses, retail clerks, teachers, and anyone who wants an extra layer of infection control protection. NanoBio Protect is available for purchase at https://www.dqeready.com/NanoBioProtect.

About DQE

Headquartered in Indianapolis, Indiana, DQE designs and sells essential emergency preparedness products that healthcare workers, emergency responders, and workplaces depend on to enhance safety and health. Learn more about DQE and its family of products at https://www.dqeready.com.

Share article on social media or email: